Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYL1801 in Neovascular AMD
NCT05637255Phase 2Completed
- Sponsor
- Sylentis
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 3
01
Overview
A Phase 2 trial of SYL1801 in neovascular age-related macular degeneration (NVAMD), sponsored by Sylentis. Started Nov 2022; status: completed.
02
Drugs
SYL1801
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05637255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05637255.